As 2025 comes to a close, it is clear that this has been a defining year for Glooko and for the broader evolution of diabetes care. Following the close of our Series F, we entered the year with a clear focus: deliver on our strategy, expand our global impact, and continue building technology that helps make diabetes care more connected, actionable, and human.
Accelerating our Mission through Strategic Leadership and a Connected Care Continuum
Over the past year, we reached several important milestones in support of that goal. We expanded our capabilities through the acquisition of Monarch Medical Technologies and its EndoTool Glucose Management System, bringing together complementary capabilities across outpatient and inpatient diabetes and glycemic management.
We strengthened our ecosystem with the launch of our Abbott FreeStyle Libre integration in the U.S., helping ensure that critical glucose data can flow more seamlessly to people with diabetes and their care teams.
We also reinforced our clinical leadership with the appointment of Mark Clements, M.D., Ph.D., as Chief Medical and Strategy Officer, underscoring our commitment to evidence-based innovation and strong clinical partnership.
Driving Digital Health Adoption in EMEA
We also saw meaningful traction across geographies and care settings.
In EMEA, we continued to expand our presence as health systems look for scalable, interoperable digital solutions to support diabetes care. At the same time, Glooko XT, our remote monitoring solution available only in France, introduced new features and strengthened its gestational diabetes management capability, an area where timely insights and coordinated care are critical for both maternal and fetal outcomes. These areas of momentum reflect the growing demand for digital tools that can support diverse patient populations and clinical workflows.
Further Enhancing our Diabetes Management Platform to Improve Care
On the product front, we continued to invest in tools designed for the realities of care delivery.
The launch of the new Glooko clinic dashboard marked an important step forward in helping clinics and health systems move beyond raw data to clearer insights, enabling more informed, timely decisions at the point of care. Across the organization, we remained focused on bringing teams together around a shared mission and shared standards, ensuring that our growth continues to be purposeful and aligned.
A reality faced by care teams each day is the need for timely, actionable data within existing clinical workflows. That’s why we invested further into our EHR capabilities this year and joined the Epic Showroom to make it easier for hospitals and health systems to seamlessly integrate their EHR with Glooko, helping reduce clinician burnout and optimize clinical workflows.
The Glooko Mobile App for people with diabetes also continued to innovate in 2025 with a redesigned food tracker for more insightful nutrition data and insights, revised insulin cards for more clarity, and viewable GLP-1 doses. These enhancements enable care teams to make more informed and timely treatment decisions between appointments using their patients’ health data – all viewable in one place.
How the U.S. Healthcare System is Moving Toward Data-Driven, Accountable Diabetes Care
These milestones matter, but they are occurring against a broader backdrop of change in healthcare that strongly validates this direction. The latest American Diabetes Association’s Standards of Care reinforce what clinicians and people with diabetes have long understood: technology-enabled management and data-driven insights are now foundational to delivering high-quality diabetes care.
At the same time, policy initiatives such as the CMS ACCESS program signal a growing emphasis on interoperability, data liquidity, and the responsible use of health data to improve outcomes at scale.
Together, these shifts point to a future in which diabetes care is increasingly proactive rather than reactive, and where data is not simply collected, but translated into meaningful action.
Regulatory momentum is reinforcing the importance of consistent, evidence-based glycemic management across care settings. CMS’s upcoming electronic clinical quality measure (eCQM) requirements for inpatient glycemic management, expected to take effect in 2026, reflect a growing emphasis on standardization, measurement, and accountability in hospital-based diabetes care. Solutions like EndoTool are at the forefront of this shift, helping health systems operationalize best practices, support clinical decision-making, and drive more reliable glycemic outcomes at scale.
For healthcare providers and care teams, this evolution brings both opportunity and urgency. As care becomes more continuous and data-rich, success depends on having tools, like Glooko’s EHR integrations, that reduce complexity, surface what matters most, and fit naturally into clinical workflows. The goal is not more data for its own sake, but clearer insight that supports better decisions and more personalized care.
For health systems, the focus is expanding to population-level impact. Managing chronic disease across diverse populations requires platforms that enable earlier intervention, more consistent care, and coordination across settings. Interoperable digital solutions, like Glooko, are becoming essential infrastructure for balancing quality, efficiency, and cost in an increasingly complex care environment.
Leveraging Scalable Healthcare Technology to Deliver Consistent Diabetes Care Around the World
Globally, the stakes are even higher. Diabetes prevalence continues to rise across regions with very different healthcare resources and delivery models. Scalable digital health solutions offer a path to extend evidence-based care, support clinicians, and bring greater consistency to diabetes management worldwide. As global standards and policies evolve, technology will play a central role in enabling more equitable access to high-quality care.
The Road Ahead for Glooko
Looking ahead, our focus at Glooko remains clear. We will continue investing in platforms that turn diabetes data into insight, insight into action, and action into better outcomes. We will deepen partnerships across the ecosystem and stay closely aligned with clinicians, health systems, and people with diabetes as their needs continue to evolve.
2025 was a year of momentum for Glooko. More importantly, it reinforced why our mission matters. As the future of diabetes care continues to take shape, we are energized by the opportunity to help lead the way.
EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions.